American Kidney Fund's Kidney Health for All™ Health Equity Media Campaign Expands to More Communities Nationwide
ROCKVILLE, Md., May 19, 2025 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) has launched the next phase of its national Kidney Health for All™ media campaign, connecting millions more people with resources to help prevent kidney disease in high-risk populations.
Part of AKF's Kidney Health for All™ health equity program, the media campaign first launched in 2024 to raise awareness about kidney disease prevention and management among Black and Hispanic/Latino people who are at greatest risk of kidney failure. In the U.S., the prevalence of kidney failure among Black people is more than four times that of white people, while the prevalence of kidney failure in Hispanic or Latino people is more than twice that of non-Hispanic white people, according to the U.S. Renal Data System.
'Our mission in launching Kidney Health for All was simple: to help ensure that all Americans, regardless of race, ethnicity or background, can access the tools and information they need to help prevent and effectively manage kidney disease,' said LaVarne A. Burton, AKF President and CEO. 'Our critical work to address health disparities is ongoing, and we are grateful for the continuing support of all those who have joined in our efforts to fight kidney disease on all fronts.'
The media campaign employs TV, streaming and radio PSAs, digital advertising, and videos in primary care offices nationwide. It also features ads on billboards and public transportation in metropolitan areas with high rates of kidney disease; these billboards and public transit ads have now expanded to eight additional markets, for a total of 16: Atlanta, Baltimore, Chicago, Detroit, Houston, New Orleans, Philadelphia, San Antonio, Washington, D.C.; Birmingham, Alabama; Columbia, South Carolina; Jackson, Mississippi; Little Rock, Arkansas; Memphis, Tennessee; Richmond, Virginia; and Sacramento, California.
AKF's Kidney Health for All health equity program addresses four areas of kidney health: prevention and awareness, increasing use of home dialysis, diversifying participation in clinical trials and increasing access to transplant.
As part of this work, AKF established and convened the Health Equity Coalition in 2021. This coalition is comprised of organizations, patients and caregivers and helps guide the development of evidence-based programs and resources for AKF's patient and professional audiences.
Since the launch of the program, AKF has developed a number of award-winning resources, including Your Guide to Kidney Transplant and the Home Dialysis Decision Aid, with more resources for people living with kidney disease and those at risk coming soon.
AKF has also created a health equity training program, which connects advocates to each other, teaches effective advocacy techniques, helps attendees develop an understanding of health equity impacting people with kidney disease and empowers attendees to advocate for laws, policies and regulations that impact the kidney community.
Additionally, AKF is now in its second year of its Kidney Health Coach (KHC) Health Equity Grant program, which helps expand the reach and impact of KHC by empowering organizations and coaches across the country to reach at-risk communities and spread health messaging in chronic kidney disease (CKD) prevention and management. So far, AKF has awarded 48 coaches and eight organizations with grants.
AKF's Kidney Health for All program can be viewed at kidneyhealthforall.org.
Kidney Health for All is supported by Presenting Sponsors Boehringer Ingelheim and Lilly and Company and Vertex Pharmaceuticals, Inc. and Equity Sponsors AstraZeneca, Merck and Co., Otsuka America Pharmaceutical, Inc., Sanofi and Travere Therapeutics.
About the American Kidney Fund
The American Kidney Fund (AKF) fights kidney disease on all fronts as the nonprofit with the greatest direct impact on people with kidney disease. AKF works on behalf of 1 in 7 Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. AKF fights for kidney health for all through programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy. AKF is one of the nation's top-rated nonprofits, investing 97 cents of every donated dollar in programs, and it has received 24 consecutive 4-Star ratings from Charity Navigator as well as the Platinum Seal of Transparency from Candid, formerly known as GuideStar.
For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn.
CONTACT: Nancy Gregory American Kidney Fund (240) 292-7077 ngregory@kidneyfund.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Former MuchMusic VJ Juliette Powell, 54, died 'unexpectedly': What to know about bacterial meningitis
Juliette Powell, a former MuchMusic VJ and author, has died. The 54-year-old, who appeared on Canadian television in the '90s as a host of Electric Circus and French Kiss died on June 3 after a brief illness. According to her obituary, Powell, who was born in the U.S. but raised in Montréal, "succumbed unexpectedly" due to acute bacterial meningitis. "Juliette had a magical way of drawing people in with her infectious enthusiasm, and her brilliant intelligence and gorgeous smile lit up every room she ever entered," reads her obituary. "Her loss is devastating and she will be deeply, painfully missed by so many." This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle. In 1989, Powell became the first Black woman to be crowned Miss Canada. She joined MusiquePlus as a VJ in 1992 before going on to join MuchMusic in 1996. Eventually, she transitioned out of music and became a business reporter for CablePulse24. Following her career in television, she authored several books including The AI Dilemma: 7 Principles for Responsible Technology in 2023. So, what is bacterial meningitis and what are the signs and symptoms? Read on to learn everything you need to know about the condition. Meningitis is the inflammation of the lining around the brain and spinal cord membranes, typically caused by an infection, bacteria or sometimes fungi. According to Meningitis Foundation Canada, untreated bacterial meningitis is a "medical emergency" and can be "fatal in a few hours." Those who do recover can have permanent disabilities, such as brain damage, hearing loss and learning disabilities. The condition usually spreads through close contact to bacteria or virus, such as cold or flu germs. As such, sneezing, coughing, kissing and close physical contact can cause the germs to spread. Because it is difficult to stop the transmission of bacteria, prevention is essential. Bacterial meningitis is diagnosed by a medical professional after analyzing a sample of spinal fluid from the patient. This condition can often be mistaken for another life-threatening illness, sepsis, which is the body's extreme response to infection. Sepsis happens when an infection triggers a chain reaction throughout your body. Without timely treatment, sepsis can quickly lead to tissue damage, organ failure and death. That the timing of bacterial meningitis symptoms can vary widely. Some people can get sick within a few hours of contracting the condition, while it may take others one to three days to show symptoms. Typically, early symptoms, occurring within the first six hours, include fever, headache, irritability, nausea and vomiting. Later symptoms occurring within six to 12 hours involve fever, muscle aches, leg pain and pale skin. After 12 hours, symptoms usually include cold hands and feet, stiff neck or neck pain, rash, confusion or delirium and decreasing responsiveness. If you or someone you know is experiencing any of the above symptoms, seek medical attention immediately. Certain risk factors can increase a person's risk for getting bacterial meningitis. The risk factors include: Age: Babies or young children are more likely to contract bacterial meningitis due to their weakened immune systems. That said, people of any age can develop the condition. Group settings: Meningitis tends to spread where large groups of people gather or live in close quarters, such as college dorms or music festivals. Certain medical conditions: Some medical conditions, medications or surgical procedures put people at increased risk for contracting bacterial meningitis. For example, having an HIV infection or not having a spleen can increase a person's risk for the condition. There are many ways to help prevent bacterial meningitis. Firstly, different vaccines can help protect against certain types of bacterial meningitis. There are vaccines for four types of bacteria that can cause the condition. Additionally, maintaining good health, washing your hands often, staying home when you're sick and having a strong immune system can protect us from most causes. Oftentimes we carry meningitis germs with no ill effects. However, if your immune system is compromised due to cancer treatments, HIV, organ transplants, infection or other serious health issues, speak with your doctor about how to help protect against meningitis. Lastly, seeking medical attention as soon as symptoms appear is essential. Moreover, as the condition is contagious, if you've been around someone who has it, call your healthcare provider to discuss how to keep from getting sick.
Yahoo
2 hours ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
ColonBroom GLP-1 Booster Website Updated to Highlight Daily Supplement for Metabolic Health
New website update showcases natural GLP-1 support supplement designed to curb cravings, support metabolism, and promote healthy weight management SAN FRANCISCO, June 10, 2025 (GLOBE NEWSWIRE) -- ColonBroom, a U.S.-based wellness brand, has announced a new update to its official website to highlight the launch of ColonBroom GLP-1 Booster—a daily supplement formulated to support metabolic function, appetite regulation, and overall weight wellness. Now available across the United States, the product offers a natural, lifestyle-friendly solution backed by science-supported ingredients. According to the official product website ( ColonBroom GLP-1 Booster is designed to work alongside the body's internal systems by promoting satiety, curbing cravings, and supporting blood sugar balance. The formula targets key wellness goals like reducing excess visceral fat and helping users manage weight more effectively without relying on restrictive diets or intense routines. 'ColonBroom GLP-1 Booster reflects our mission to simplify wellness with natural tools that align with modern lifestyles,' said a company spokesperson. 'This formula is designed with purpose—combining evidence-backed ingredients for those seeking real metabolic support.' The formulation includes Berberine, Chromium Picolinate, 5-HTP, Saffron Extract, and Bupleurum Root Extract—ingredients selected for their known roles in supporting GLP-1 activity, blood sugar balance, mood regulation, and fat metabolism. ColonBroom confirms that all supplements are manufactured in facilities that adhere to rigorous quality and safety protocols. The brand offers a satisfaction guarantee for new customers and invites visitors to explore ingredient insights, customer FAQs, and personalized quiz recommendations directly on the website. About ColonBroom ColonBroom is a San Francisco-based wellness brand dedicated to creating clean, effective, and easy-to-use daily supplements. With a focus on transparency and science-backed simplicity, ColonBroom empowers adults to take proactive steps toward digestive and metabolic wellness. Product and Contact Information Brand: ColonBroomWebsite: hello@ (Order Support): 1-888-505-0855Mailing Address: 505 Montgomery Street, 10th & 11th Floors, San Francisco, California, 94111, USA Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. CONTACT: Email: hello@ Phone (Order Support): 1-888-505-0855Sign in to access your portfolio
